CDKN2A and cancer: Some molecular mechanisms underlying the role of Bmi1 in cancer development or progression have been proposed, such as inhibition of the tumor suppressors p16INK4a and p19ARF (p14ARF in humans) [25], and PTEN to promote EMT (epithelial-mesenchymal transition) and malignancy [26].